AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive the FDA has approved the first human trial of the company's lead drug Ampligen with interferon alfa-2b in treating cancer patients battling the coronavirus.
Equels says the new clinical trial will be conducted at Roswell Park Comprehensive Cancer Center, where a Phase 1/2b of the study will enroll around 40 patients in two stages.
Price: 2.775 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
AIM ImmunoTech Inc (NYSE American: AIM) CEO Thomas Equels tells Proactive the Florida-based biopharma group is working on setting up its pre-clinical structure to allow it to begin clinical trials to treat the coronavirus with its lead drug Ampligen. What's more, Equels says the firm recently...
Prev article
